NeOnc Technologies will host an investor call on November 12, 2025, presenting updates from their NEO100 clinical trial.
Quiver AI Summary
NeOnc Technologies Holdings, Inc. has announced an investor conference call and webcast scheduled for November 12, 2025, to provide updates on their ongoing Phase 1/2a NEO100-1 clinical trial and the compassionate use program for NEO100, targeting recurrent high-grade malignant glioma. The management team and members of the Scientific Advisory Board will discuss MRI-based radiographic responses, as well as trends in progression-free and overall survival among patients. The company, which develops brain-penetrant therapeutics for CNS disorders, is advancing its drug candidates NEO100 and NEO212 under FDA Fast-Track status, backed by a strong patent portfolio licensed from the University of Southern California. The press release also includes standard cautionary statements regarding forward-looking statements and potential risks.
Potential Positives
- NeOnc Technologies is hosting an investor conference call to present significant data updates from its ongoing Phase 1/2a NEO100-1 clinical trial, which indicates proactive communication and transparency with investors.
- Presentation of MRI-based radiographic response data, progression-free survival, and overall survival trends for NEO100 could demonstrate the therapeutic potential of the drug, which is positive for the company’s credibility and future prospects.
- NeOnc has exclusive rights to a comprehensive patent portfolio from the University of Southern California, ensuring competitive advantages and potential revenue streams through intellectual property protection.
- NEO100 and NEO212 are progressing under FDA Fast-Track and Investigational New Drug status, highlighting the company's commitment to expedited development of its promising therapeutics for CNS disorders.
Potential Negatives
- The press release mentions ongoing clinical trials, but does not provide definitive results, which may raise concerns about the effectiveness of the company's treatments.
- The inclusion of cautionary language around forward-looking statements may reflect uncertainty in the company's future performance and clinical outcomes, which could worry investors.
- The reference to the potential failure to finalize an agreement with Quazar suggests a level of unpredictability in business partnerships that could affect the company's strategic direction.
FAQ
What is the purpose of the investor conference call on November 12, 2025?
The call will present data updates from the Phase 1/2a NEO100-1 clinical trial and compassionate use program.
Who are the featured participants in the investor conference call?
Featured participants include Dr. Henry S. Friedman and Dr. Alexander Miller, along with NTHI management team members.
What is NEO100 and its significance in the clinical trial?
NEO100 is a high-purity perillyl alcohol developed for treating recurrent high-grade malignant glioma with promising trial results.
How can investors access the live webcast of the conference call?
The live webcast can be accessed by visiting the NeOnc Technologies investor website.
What are NeOnc’s main therapeutic focuses?
NeOnc focuses on developing brain-penetrant therapeutics for malignant brain tumors and central nervous system disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTHI Insider Trading Activity
$NTHI insiders have traded $NTHI stock on the open market 14 times in the past 6 months. Of those trades, 14 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTHI stock by insiders over the last 6 months:
- AMIR F HESHMATPOUR (President) has made 7 purchases buying 12,000 shares for an estimated $121,299 and 0 sales.
- THOMAS C CHEN (CEO) has made 3 purchases buying 5,868 shares for an estimated $42,802 and 0 sales.
- JIM DELSHAD purchased 5,000 shares for an estimated $36,110
- KEITHLY GARNETT (CFO) has made 3 purchases buying 900 shares for an estimated $6,527 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NTHI Hedge Fund Activity
We have seen 3 institutional investors add shares of $NTHI stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HIGHPOINT ADVISOR GROUP LLC added 769,163 shares (+424.8%) to their portfolio in Q3 2025, for an estimated $6,984,000
- SLT HOLDINGS LLC added 11,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $99,880
- FOUNDATIONS INVESTMENT ADVISORS, LLC added 11,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $99,880
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”) , a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open).
During the call, members of the NTHI management team and independent members of the company’s Scientific Advisory Board (SAB) will present data updates from the Company’s ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program, evaluating intranasal delivery of NEO100 (high-purity perillyl alcohol) in patients with recurrent high grade malignant glioma.
The discussion will highlight MRI-based radiographic response data, progression-free survival (PFS), and overall survival (OS) trends observed to date, providing important insights into long-term clinical outcomes for patients treated with NEO100.
Featured Participants:
- Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University; Independent Member, NTHI Scientific Advisory Board
- Dr. Alexander Miller, MD – Chief Neuro-oncology, Brain Tumor Program, NYU Langone Health; Independent Member, NTHI Scientific Advisory Board
-
NTHI Management Team:
- Amir Heshmatpour – Chief Executive Officer, Executive Chairman and President
- Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer and Chief Scientific Officer
- Dr. Josh Neman, PhD – Chief Clinical Officer
-
Keith Garnett – Chief Financial Officer
Conference Call Details:
- Date: Wednesday, November 12, 2025
- Time: 6:00 a.m. PT / 9:00 a.m. ET
-
Webcast:
A live webcast can be accessed by visiting
https://investors.neonc.com
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com .
Important Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
[email protected]
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
[email protected]
